Bcl-2 gene therapy - Idun/Selective Genetics

Drug Profile

Bcl-2 gene therapy - Idun/Selective Genetics

Latest Information Update: 17 Aug 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Idun Pharmaceuticals; Tissue Repair Company
  • Class Anti-ischaemics; Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Fracture; Ischaemic heart disorders; Skin ulcer; Spinal cord injuries

Most Recent Events

  • 05 Dec 2003 No development reported - Preclinical for Fracture in USA (unspecified route)
  • 05 Dec 2003 No development reported - Preclinical for Ischaemic heart disorders in USA (unspecified route)
  • 05 Dec 2003 No development reported - Preclinical for Skin ulcer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top